The clinical and molecular spectrum of ETV6 mutated myeloid neoplasms
British Journal of Haematology · 2023
DOI: 10.1111/bjh.18850 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Haematology, 2023. Verfasst von Mark Gurney und 17 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology, Mayo Clinic, Rochester, Minnesota, USA. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute, Myelodysplastic Syndromes, Myeloproliferative Disorders, Neoplasms. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 15 Literaturangaben.
Abstract (Originalsprache)
ETV6 mutations are rare but recurrent somatic events in myeloid neoplasms and are negatively prognostic in myelodysplastic syndrome. We set out to examine the clinical and molecular characteristics of patients undergoing investigation for myeloid neoplasms, found to have deleterious ETV6 mutations. ETV6 mutations occurred in 33 of 5793 (0.6%) cases investigated and predominantly in high‐risk disease entities including MDS with increased blasts, primary myelofibrosis and AML, myelodysplasia‐related. In three cases, isolated iso (17q) karyotype was concurrently detected, an otherwise rare karyotype in myeloid neoplasms. ETV6 mutations were frequently subclonal and never occurred as an isolated abnormality with ASXL1 ( n = 22, 75%), SRSF2 ( n = 14, 42%) and SETBP1 ( n = 11, 33%) the predominant co‐mutations. Restricting to patients with MDS, higher rates of ASXL1, SETBP1, RUNX1 and U2AF1 mutations occurred in ETV6 mutated cases, relative to a consecutive control cohort with wild‐type ETV6 . The median OS of the cohort was 17.5 months. This report highlights the clinical and molecular associations of somatic ETV6 mutations in myeloid neoplasms, suggests their occurrence as a later event, and proposes further translational research questions for their role in myeloid neoplasia.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Hematology, Mayo Clinic, Rochester, Minnesota, USA.
ORCID-Profile: Mark Gurney, Anmol Baranwal, James M Foran, Talha Badar, Naseema Gangat, Mithun V Shah, Rong He, Aref Al-Kali
Zitieren
APA
Gurney, M., Chekkaf, I., Baranwal, A., Basmaci, R., Katamesh, B., Greipp, P., Foran, J. M., Badar, T., Mangaonkar, A. A., Begna, K. H., Gangat, N., Patnaik, M. M., Litzow, M. R., Shah, M. V., Viswanatha, D. S., He, R., Alkhateeb, H. B., & Al-Kali, A. (2023). The clinical and molecular spectrum of ETV6 mutated myeloid neoplasms. British Journal of Haematology. https://doi.org/10.1111/bjh.18850
Vancouver
Gurney M, Chekkaf I, Baranwal A, Basmaci R, Katamesh B, Greipp P, et al. The clinical and molecular spectrum of ETV6 mutated myeloid neoplasms. British Journal of Haematology. 2023. doi:10.1111/bjh.18850
BibTeX
@article{Gurney2023,
author = {Gurney, Mark and Chekkaf, Ismahene and Baranwal, Anmol and Basmaci, Rami and Katamesh, Bahga and Greipp, Patricia and Foran, James M and Badar, Talha and Mangaonkar, Abhishek A and Begna, Kebede H and Gangat, Naseema and Patnaik, Mrinal M and Litzow, Mark R and Shah, Mithun V and Viswanatha, David S and He, Rong and Alkhateeb, Hassan B and Al-Kali, Aref},
title = {The clinical and molecular spectrum of ETV6 mutated myeloid neoplasms},
journal = {British Journal of Haematology},
year = {2023},
doi = {10.1111/bjh.18850}
}
EUVIMED